5White R, Walker P, Roberts S, et al. Bristol COPD Knowledge Questionnaire (BCKQ): testing what we teach patients about COPD[J]. Chron Respir Dis, 2006,3 (3) :123-131.
6Gabriel R, Figueiredo D, Jacome C, et al. Day-to-day living with severe chronic obstructive pulmonary disease: towards a family-based approach to the illness impacts [J]. Psychol Health, 2014,29(8) : 967-983.
7Jaeome C, Figueiredo D, Gabriel R, et al. Predicting anxiety and depression among family carets of people with chronic obstructive pulmonary disease[J]. Int Psy- chogeriatr,2014,26(7) :1191-1199.
8BETHKE TD, BOHMER GM, HERMANN R, et al. Dose- proportional intraindividual single- and repeated- dose pharma- cokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor[J]. J Clin Pharmaeol, 2007, 47 ( 1 ) : 26-36.
9KNEBEL NG, HERZOG R, REUTTER F, et d. Sensitive quantification of rotlumilast and rotlumilast N-oxide in human plasma by LC- MS/MS employing parallel chromatography and eleetrospray ionisation[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2012, 893-894: 82-91.
10THAPPALI SR, VARANASI KV, VEERARAGHAVAN S, et ~d. Simultaneous quantitation of IC87114,rflumilast and its active metabolite roflumilast N- oxide in plasma by LC-MS/MS: application for a pharmaeokinetic study [J]. J Mass Speetrom, 2012, 47(12): 1612-1619.
